Superluminal Advances Selective MC4R Agonist Toward IND Studies
Compound to be evaluated as a potentially best-in-class treatment for rare genetic forms of obesity and hypothalamic obesity, as well as part of the treatment regimen for adult obesity patients In preclinical studies, the molecule demonstrated high selectivity, a broad therapeutic window, and a favorable safety profile compared to existing treatments and those in development…
